Hennion & Walsh Asset Management Inc. Purchases 218,383 Shares of Day One Biopharmaceuticals, Inc. $DAWN

Hennion & Walsh Asset Management Inc. grew its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 229.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 313,455 shares of the company’s stock after purchasing an additional 218,383 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Day One Biopharmaceuticals were worth $2,921,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in DAWN. Rubric Capital Management LP purchased a new stake in shares of Day One Biopharmaceuticals in the third quarter worth $23,808,000. AIGH Capital Management LLC purchased a new position in Day One Biopharmaceuticals during the third quarter worth about $10,719,000. Mak Capital One LLC bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth about $10,212,000. Balyasny Asset Management L.P. bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth about $9,758,000. Finally, Millennium Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 587.2% in the 1st quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock valued at $10,468,000 after acquiring an additional 1,127,995 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Up 0.1%

NASDAQ DAWN opened at $21.44 on Wednesday. The stock’s 50-day simple moving average is $15.03 and its two-hundred day simple moving average is $10.75. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.64 and a twelve month high of $21.46. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -20.82 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The firm had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Lauren Merendino sold 5,814 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $67,442.40. Following the transaction, the insider directly owned 60,157 shares of the company’s stock, valued at approximately $697,821.20. This trade represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,461 shares of company stock worth $422,948 over the last ninety days. Corporate insiders own 6.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. HC Wainwright reiterated a “neutral” rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $21.50 target price (down from $27.00) on shares of Day One Biopharmaceuticals in a research note on Wednesday, March 11th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Friday, March 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. Finally, TD Cowen lowered shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 6th. One investment analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Hold” and an average price target of $23.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.